This page shows what was measured, who it was measured in, and what that does not settle.
What Abiraterone Acetate does in the body
(1) metastatic high-risk castration-sensitive prostate cancer (CSPC).
From the FDA-approved label: Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor, that inhibits 17 α-hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed in testicular, adrenal, and prostatic tumor tissues and is required for androgen biosynthesis. CYP17 catalyzes two sequential reactions: 1) the conversion of pregnenolone and progesterone to their 17α-hydroxy derivatives by 17α-hydroxylase activity and 2) the subsequent formation of dehydroepiandrosterone (DHEA) and androstenedione, respectively, by C17, 20-lyase activity. DHEA and androstenedione are androgens and are precursors of testosterone.
Why people take it. (1) metastatic high-risk castration-sensitive prostate cancer (CSPC).
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · EM5OCB9YJ6 · read 2026-08-29
Its recorded molecular formula is C26H33NO2, weighing 391.55.
US prescribing information · c9eb9b46-f847-40a8-802c-a51b40406d5a · read 2026-08-30
Where each sentence above came from
The use the label states, quoted from it. No plain-language version of this sentence has been written.
The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.
No statement of the main limit is recorded.
The four opening statements run to 109 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Enzyme
An enzyme is a protein that speeds up one chemical change.
A picture of it, and where the picture fails
An enzyme is like a machine on a production line doing one cut.
Where that stops being true. A machine is switched on and off by a person. Enzymes are controlled by the cell.
What people get wrong. Enzymes are thought to be used up. They are not; they work again and again.
A catalytic protein that lowers the activation energy of a specific reaction.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What was measured, goal by goal
One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.
Registered studies list 40 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.
There is no single score. A strong test result and a weak life result are different facts.
Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
Goal
Life outcome
What a body can do
How a person feels
A test result
A step in the body
Harms
How long
Who was studied
Fertility and sexual health
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
△Only a number moved1 registered test measure.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
Fertility and sexual health
detectable bone marrow testosterone level; testosterone concentration in prostate tissue
Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.
What each mark on this table means
∅ Nothing in the sources checked
No registered study lists a life outcome for this goal.
△ Only a number moved
1 registered test measure.
— Not recorded
Harms were not a registered measure for this goal.
… Waiting for a reviewer
Who was studied is listed further down the page.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Overall survival
✗ The study did not show it
Who was studied
NCT00268476
How many people
11992
Study design
Phase 2/Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
✗ The study did not show it
Who was studied
NCT07620574
How many people
5000
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Overall Survival (OS)
✗ The study did not show it
Who was studied
NCT06320067
How many people
3360
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Radiographic Progression-Free Survival (rPFS)
✗ The study did not show it
Who was studied
NCT06120491
How many people
1898
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
overall survival
✗ The study did not show it
Who was studied
NCT05974774
How many people
1600
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Overall survival (primary efficacy)
✗ The study did not show it
Who was studied
NCT07751133
How many people
1500
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.7 registered measures of this kind. 5 written-up studies measured this and did not show a benefit.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
□Symptoms and quality of lifeNo evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.No registered study measures this.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.3 registered measures of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Mouse. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
No registered study measured anything of this kind.
Measured
Things only a test, a scale or a device shows.
testosterone concentration in prostate tissue
dihydrotestosterone concentration in prostate tissue
maximum observed plasma concentration of pioglitazone
Meaningful
Things that change how a life goes, not only a number.
overall survival
radiographic progression free survival
phase ii radiographic progression free survival
progression free survival
prostate specific antigen free survival
survival
symptomatic skeletal event free survival
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (30)
confirmed prostate specific antigen response at week 12
prostate specific antigen response
detectable bone marrow testosterone level
detectable bone marrow dihydrotestosterone level
time to treatment failure
undetectable psa
androgen receptor related mutations
phase ib percentage of dose limiting toxicities
phase ib percentage of adverse events
serious adverse events
maximum tolerated dose
adverse events
affected by an adverse event
anti tumor responses as defined by a decline in psa of 50
response proportion as defined by a decline in psa of 50
soft tissue complete response
achieving prostate specific antigen response up to 12 weeks
achieving prostate specific antigen response at week 12
differences in genomic expression and biological activity
clinical benefit rate
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What it would be like to take◇Read from sources, not yet reviewed
How long anything takes
Nine different lengths of time that get confused with each other. None of them is worked out from another.
Before anything is noticed.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before a test result moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before performance moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
How long the result was watched.No finished study window is recorded for a study that tested this substance.
How long people took it.How long people actually took it is not stored. The study window is not the same thing.
How long people were followed.Follow-up length is not stored separately. It is never read off the study window, which would be a different thing.
How fast the body clears it. 12 ± 5 hours hours
Read from the label, which states: “Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.”
How long effects linger.RNAWiki does not store this separately, and never works it out from another figure on this page.
Beyond the studies. Nothing is recorded about the long term.
The longest finished study sets the edge of what anyone measured.
A study window is not how long people took it, and neither is how long they were followed. Where RNAWiki holds only one of the three, it shows one.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with • Metastatic castration-resistant prostate cancer (CRPC) • Metastatic high-risk castration-sensitive prostate cancer (CSPC) Abiraterone acetate tablets are a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with • metastatic castration-resistant prostate cancer (CRPC).
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “Safety and effectiveness of abiraterone acetate in pediatric patients have not been established.”
US prescribing information · c9eb9b46-f847-40a8-802c-a51b40406d5a · read 2026-08-30
On older people, the label states: “Of the total number of patients receiving abiraterone acetate in randomized clinical trials, 70% of patients were 65 years and over and 27% were 75 years and over.”
US prescribing information · c9eb9b46-f847-40a8-802c-a51b40406d5a · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary The safety and efficacy of abiraterone acetate have not been established in females.”
US prescribing information · c9eb9b46-f847-40a8-802c-a51b40406d5a · read 2026-08-30
On people who are breastfeeding, the label states: “8.3 Females and Males of Reproductive Potential Contraception Males Based on findings in animal reproduction studies and its mechanism of action, advise males with female partners of reproductive potential to use effective contraception during treatment and for 3 weeks after the final dose of abiraterone acetate [see Use in Specific Populations (8.1) ] .”
US prescribing information · c9eb9b46-f847-40a8-802c-a51b40406d5a · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S1, S3, S4.
No source is stored against this line.
What is in the pack
Sold as tablet, tablet, film coated, given by the oral route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Abiraterone Acetate appears in spontaneous reports to regulators. Across the 9 most-reported reaction terms, 2360 reaction mentions were counted. One report can name several reactions.
The recorded terms (9)
prostatic specific antigen increased — 541 reaction mentions
disease progression — 516 reaction mentions
hypokalaemia — 355 reaction mentions
hospitalisation — 331 reaction mentions
hot flush — 275 reaction mentions
prostate cancer — 192 reaction mentions
prostate cancer metastatic — 139 reaction mentions
drug hypersensitivity — 10 reaction mentions
injection site pain — 1 reaction mentions
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
76 products list this as an active ingredient in the United States drug directory. 74 of them contain it and nothing else.
FDA National Drug Code directory · 71921-177 · read 2026-08-29
They are sold as powder, tablet and tablet, film coated, taken oral.
FDA National Drug Code directory · 71921-177 · read 2026-08-29
The regulator's established pharmacologic class for it is cytochrome p450 17a1 inhibitor [epc], cytochrome p450 17a1 inhibitors [moa] and cytochrome p450 2c8 inhibitors [moa].
FDA National Drug Code directory · 71921-177 · read 2026-08-29
32 published labels name it as an active ingredient. 31 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · c9eb9b46-f847-40a8-802c-a51b40406d5a · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · c9eb9b46-f847-40a8-802c-a51b40406d5a · read 2026-08-29
Abiraterone Acetate is oral at 3 DOSAGE FORMS AND STRENGTHS Abiraterone acetate tablets USP, 250 mg are white to off-white, oval-shaped, uncoated tablets debossed with “AN65” on one side and plain on the other side., recorded as fda label in effect 2023-08-14 in the United States.
US prescribing information · c9eb9b46-f847-40a8-802c-a51b40406d5a · read 2026-08-30
Recorded price in US: 0.77462–2.76755 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 35 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Abiraterone Acetate studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Abiraterone Acetate are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
How many documents were read
31 documents were read for this substance.
RNAWiki source record
2 of them state the same proteinBinding, and they agree.
RNAWiki source record
31 of them state the same volumeOfDistribution, and they agree.
RNAWiki source record
Where else this substance is registered
FDA substance identifier (UNII)
EM5OCB9YJ6
RxNorm concept
1100075
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Quoted from a stored source.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S1, S3, S4.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
18 approved applications cover products containing this substance. The earliest was NDA202379, approved 20110428 to JANSSEN BIOTECH.
This order is fixed in code and does not count clicks or time on the page.
What is not here
5 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
The path through the body — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (14)
Q2
What did Abiraterone Acetate's largest trial (11992 people) and its longest (25 years) measure?
11992 people in Abiraterone Acetate's largest registered study, 25 years in its longest registered window, measuring Physical function: 400m Walk. ClinicalTrials.gov · 2026-09-01
171 phase2, 82 phase1, 44 phase3, 23 na or unstated, 6 phase4, 3 early phase1, 3 na; NCT00268476; 2030-12; no ageing endpoint recorded. Last human test completed 2026, NCT03860987.
Interpretation These counts include studies where Abiraterone Acetate was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase2
171
phase1
82
phase3
44
na or unstated
23
phase4
6
early phase1
3
2 more recorded rows
na
3
Last recorded human testNCT03860987
2026-05-18
recorded 2026-09-01 · last checked 2026-09-04
Q3
From mouse to human: where has Abiraterone Acetate shown healthspan?
withdrawn; "Sponsor determined study is not required according to PFDA Circular 2013-004"
NCT01717898
terminated; "Dose limiting toxicities on lowest dose level"
NCT01735396
terminated; "poor accrual"
NCT01741753
terminated; "Due to slow accrual the supllier of BKM120 asked we cease further enrollment."
NCT01814865
withdrawn; "Funding was not acquired"
14 further recorded trials
NCT01828476
terminated; "The Investigator left the organization."
NCT01845792
terminated; "Low accrual"
NCT01913015
terminated; "After enrollment of the first 3 subjects, an interim assessment was conducted. Comparing DBS sampling to plasma PK levels yielded unconvincing results."
NCT01994590
terminated; "Sponsor stopped supplying study drug"
NCT01995058
terminated; "Sponsor decided to close the study prior to completion of enrollment. This was a business decision and not based on the safety results of the study."
NCT02125617
terminated; "Poor recruition"
NCT02159690
withdrawn; "loss of funding"
NCT02379390
terminated; "Unsatisfactory patient accrual"
NCT02380313
withdrawn; "Study cancelled: Withdrawn before enrollment of any participants"
NCT02574910
terminated; "The study has been affected significantly by the COVID pandemic, drug supply/drug amendment, low recruitment interest, and FDA approval of another drug with the same indication, so this study has not met its primary endpoint data…"
NCT02608359
withdrawn; "No subjects recruited in the study"
NCT02656615
terminated; "Lack of Patient accrual"
NCT02711137
terminated; "Study terminated due to safety issues."
NCT02758132
terminated; "Low accruals"
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Abiraterone Acetate used Abiraterone acetate, 250 mg (uncoated, current commercial tablet) — over how long?
Abiraterone Acetate's half-life is 12 ± 5 hours — which schedules were studied?
12 ± 5 hours, the half-life Abiraterone Acetate's label states. openfda-label · c1200e4e-c4f7-9067-e053-2a95a90af509 · 2026-08-30
Show the evidence
half life
12 ± 5 hours hours; Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
metabolism
Metabolism Following oral administration of 14 C-abiraterone acetate as capsules, abiraterone acetate is hydrolyzed to abiraterone (active metabolite).
recorded 2026-08-30 · last checked 2026-09-04
Q7
Which of achieving prostate specific antigen response at week 12, achieving prostate specific antigen response up to 12 weeks and adverse events did Abiraterone Acetate's trials measure?
achieving prostate specific antigen response at week 12, achieving prostate specific antigen response up to 12 weeks and adverse events lead 40 outcome terms across Abiraterone Acetate's trials. ClinicalTrials.gov · 2026-09-01
Interpretation detectable bone marrow testosterone level, detectable bone marrow dihydrotestosterone level, radiographic progression free survival, testosterone concentration in prostate tissue, dihydrotestosterone concentration in prostate tissue and time to treatment failure follow.
Show the evidence
overall survival
1
confirmed prostate specific antigen response at week 12
1
prostate specific antigen response
1
detectable bone marrow testosterone level
1
detectable bone marrow dihydrotestosterone level
1
radiographic progression free survival
1
14 more recorded rows
testosterone concentration in prostate tissue
1
dihydrotestosterone concentration in prostate tissue
1
time to treatment failure
1
undetectable psa
1
androgen receptor related mutations
1
phase ib percentage of dose limiting toxicities
1
phase ib percentage of adverse events
1
phase ii radiographic progression free survival
1
serious adverse events
1
progression free survival
1
maximum tolerated dose
1
adverse events
1
affected by an adverse event
1
anti tumor responses as defined by a decline in psa of 50
1
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which of Abiraterone Acetate's 99 ongoing trials reports first?
"Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy"; n 11992; "Overall survival"; 2030-12
NCT01786265
"Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer"; n 310; "Prostate-specific antigen (PSA) free survival (PSA < 0.1 ng/ml)"; 2027-02-01
NCT01957436
"A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer"; n 1173; "Survival"; 2032-12
NCT02123758
"A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer"; n 57; "Area Under the Plasma Concentration-time Curve From Time Zero to Time 24 Hours (AUC [0-24]) of abiraterone"; 2027-12-31
NCT02257736
"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)"; n 982; "Radiographic Progression-free Survival (rPFS)"; 2027-12-31
NCT02415621
"Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer"; n 19; "Prostatic Specific Antigen (PSA) Response Rate"; 2026-07
14 further recorded trials
NCT02703623
"Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer"; n 196; "Overall survival (OS)"; 2028-03-31
NCT02807805
"Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer"; n 37; "PSA response rate"; 2025-12
NCT02861573
"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)"; n 1200; "Percentage of Participants With a Decrease of ≥50% in Prostatic Specific Antigen (PSA)"; 2028-07-24
NCT02949284
"Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery"; n 90; "Post-surgical potency rate defined as successful intercourse in half the attempts"; 2027-06
NCT02960022
"A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study"; n 900; "Number of participants with adverse events"; 2029-07-31
NCT03012321
"Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects"; n 70; "Objective Progression Free Survival (PFS)"; 2027-01-16
NCT03016741
"Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer"; n 100; "Cognitive function defined by overall Cogstate score and Cogstate module scores for each domain"; 2029-08
NCT03419234
"Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel"; n 223; "Progression-free Survival (PFS)"; 2028-04-01
NCT03431350
"A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer"; n 136; "Combination 1: Part 1: Number of Participants With Specified Toxicity"; 2026-12-31
NCT03436654
"Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma"; n 102; "Pathologic Response (pCR + MRD) in the RP specimen"; 2027-02-14
NCT03511196
"Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer"; n 17; "Rate of Participant Retention"; 2026-09
NCT03678025
"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer"; n 1273; "Overall survival (OS)"; 2031-10-01
NCT03706365
"A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer"; n 393; "Radiographic Progression Free Survival (rPFS)"; 2026-12
NCT03732820
"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer"; n 895; "Number of Participants With Radiological Progression Free Survival (rPFS) Event by Investigator Assessment"; 2027-02-05
recorded 2026-09-01 · last checked 2026-09-04
Q9
Which running trial of Abiraterone Acetate could settle lifespan?
NCT04446117 measures Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC), reading out 2026-10-16.
39 open trials; n 575; "Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC"
Show the evidence
Trial
NCT04446117
"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC"; n 575; "Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC)"; 2026-10-16
NCT03706365
"A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer"; n 393; "Radiographic Progression Free Survival (rPFS)"; 2026-12
NCT03903835
"ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer"; n 750; "Progression free survival (PFS) in mCRPC"; 2026-12
NCT05457257
"Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations"; n 43; "Radiological Progression-free Survival - Based on Blinded Independent Central Review (BICR)"; 2026-12-31
NCT03012321
"Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects"; n 70; "Objective Progression Free Survival (PFS)"; 2027-01-16
NCT01786265
"Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer"; n 310; "Prostate-specific antigen (PSA) free survival (PSA < 0.1 ng/ml)"; 2027-02-01
14 further recorded trials
NCT03732820
"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer"; n 895; "Number of Participants With Radiological Progression Free Survival (rPFS) Event by Investigator Assessment"; 2027-02-05
NCT05171816
"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)"; n 110; "Radiological Progression Free Survival (rPFS)"; 2027-02-05
NCT03748641
"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer"; n 765; "Cohort 1: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR)"; 2027-02-27
NCT04493853
"Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency"; n 1012; "Radiographic Progression-free Survival (rPFS)"; 2027-03-31
NCT07553988
"A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer"; n 120; "Median Progression-free survival (PFS) at 1 year in RS-113 treatment arms"; 2027-05-09
NCT05288166
"A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)"; n 925; "Radiographic Progression-Free Survival (rPFS) Assessed by Investigator"; 2027-10
NCT04497844
"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)"; n 696; "Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-free Survival (rPFS) Assessed by Investigator"; 2027-11-01
NCT02257736
"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)"; n 982; "Radiographic Progression-free Survival (rPFS)"; 2027-12-31
NCT04647526
"Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment"; n 455; "Randomization Phase: Radiographic Progression-Free Survival (rPFS)"; 2028-03
NCT02703623
"Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer"; n 196; "Overall survival (OS)"; 2028-03-31
NCT03419234
"Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel"; n 223; "Progression-free Survival (PFS)"; 2028-04-01
NCT04947254
"Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer"; n 200; "Composite radiographic progression-free survival(rPFS) and biochemical (PSA) progression-free survival (PFS)"; 2028-06-07
NCT05189457
"First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer"; n 32; "Overall Survival"; 2028-07
NCT06473259
"Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients"; n 3000; "progression free survival"; 2028-12
Q10
Which 47 trials of Abiraterone Acetate posted no result?
Posted no result
47 of 47 completed trials
Registrations
NCT02001571, NCT01362764, NCT01655147, NCT01017939, NCT00910754 and NCT01640093, and 41 more
Completion dates
oldest 2010-04; newest 2024-08-13
Show the evidence
Trial
NCT02001571
2010-04
NCT01362764
2011-06
NCT01655147
2012-03
NCT01017939
2012-04
NCT00910754
2012-05
NCT01640093
2012-07
14 further recorded trials
NCT01664728
2012-09
NCT01678573
2012-09
NCT01495910
2013-02
NCT01873001
2013-07
NCT01795703
2014-10
NCT01756638
2014-10-17
NCT02230046
2014-11
NCT01685268
2014-12
NCT00755885
2016-06-04
NCT02887976
2017-10-06
NCT02405858
2017-12-31
NCT01677897
2018-06
NCT01842321
2018-07-04
NCT02353715
2018-11-14
Q11
At the median, Abiraterone Acetate's trials enrolled 60.5 people — anything larger?
Median enrolment
60.5
Largest enrolment
11992
Registered trials counted
296
Q12
What do 2360 spontaneous reports say about Abiraterone Acetate — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Abiraterone Acetate appears in spontaneous reports to regulators. Across the 9 most-reported reaction terms, 2360 reaction mentions were counted: prostatic specific antigen increased 541; disease progression 516; hypokalaemia 355; hospitalisation 331. open-targets-adr · CHEMBL271227 · 2026-06-24
Show the evidence
prostatic specific antigen increased
541
disease progression
516
hypokalaemia
355
hospitalisation
331
hot flush
275
prostate cancer
192
3 more recorded rows
prostate cancer metastatic
139
drug hypersensitivity
10
injection site pain
1
recorded 2026-06-24 · last checked 2026-09-04
Q13
Abiraterone Acetate and CYP3A4, CYP1A2 and CYP2C8: shared by which compounds?
CYP3A4, CYP1A2 and CYP2C8 appear in Abiraterone Acetate's recorded interaction sentences, 13 in all. openfda-label+europepmc · 2026-08-30
Interpretation pharmacokinetics
Show the evidence
CYP1A2
pharmacokinetics
CYP1A2 substrates : When abiraterone acetate 1,000 mg daily (plus prednisone 5 mg twice daily) was given with a single dose of 100 mg theophylline (CYP1A2 substrate), no increase in systemic exposure of theophylline was observed.
pharmacokinetics
In Vitro Studies Cytochrome P450 (CYP) Enzymes: Abiraterone is a substrate of CYP3A4 and has the potential to inhibit CYP1A2, CYP2D6, CYP2C8 and to a lesser extent CYP2C9, CYP2C19 and CYP3A4/5.
CYP2C19pharmacokinetics
In Vitro Studies Cytochrome P450 (CYP) Enzymes: Abiraterone is a substrate of CYP3A4 and has the potential to inhibit CYP1A2, CYP2D6, CYP2C8 and to a lesser extent CYP2C9, CYP2C19 and CYP3A4/5.
CYP2C8
pharmacokinetics
In Vitro Studies Cytochrome P450 (CYP) Enzymes: Abiraterone is a substrate of CYP3A4 and has the potential to inhibit CYP1A2, CYP2D6, CYP2C8 and to a lesser extent CYP2C9, CYP2C19 and CYP3A4/5.
pharmacokinetics
CYP2C8 substrates: The AUC of pioglitazone (CYP2C8 substrate) was increased by 46% when pioglitazone was given to healthy subjects with a single dose of 1,000 mg abiraterone acetate.
CYP2C9pharmacokinetics
In Vitro Studies Cytochrome P450 (CYP) Enzymes: Abiraterone is a substrate of CYP3A4 and has the potential to inhibit CYP1A2, CYP2D6, CYP2C8 and to a lesser extent CYP2C9, CYP2C19 and CYP3A4/5.
CYP2D6
pharmacokinetics
In Vitro Studies Cytochrome P450 (CYP) Enzymes: Abiraterone is a substrate of CYP3A4 and has the potential to inhibit CYP1A2, CYP2D6, CYP2C8 and to a lesser extent CYP2C9, CYP2C19 and CYP3A4/5.
pharmacokinetics
Effect of Abiraterone acetate on Other Drugs CYP2D6 substrates : The C max and AUC of dextromethorphan (CYP2D6 substrate) were increased 2.8-and 2.9-fold, respectively when dextromethorphan 30 mg was given with abiraterone acetate 1,000 mg daily (plus prednisone 5 mg twice daily).
CYP3A4
pharmacokinetics
CYP3A4 and SULT2A1 are the enzymes involved in the formation of N-oxide abiraterone sulphate and SULT2A1 is involved in the formation of abiraterone sulphate.
pharmacokinetics
Strong CYP3A4 inhibitors : Co-administration of ketoconazole, a strong inhibitor of CYP3A4, had no clinically meaningful effect on the pharmacokinetics of abiraterone.
pharmacokinetics
In Vitro Studies Cytochrome P450 (CYP) Enzymes: Abiraterone is a substrate of CYP3A4 and has the potential to inhibit CYP1A2, CYP2D6, CYP2C8 and to a lesser extent CYP2C9, CYP2C19 and CYP3A4/5.
pharmacokinetics
Drug Interaction Studies Clinical Studies Effect of Other Drugs on Abiraterone acetate Strong CYP3A4 inducers : .
pharmacokinetics
In a clinical pharmacokinetic interaction study of healthy subjects pretreated with a strong CYP3A4 inducer (rifampin, 600 mg daily for 6 days) followed by a single dose of abiraterone acetate 1,000 mg, the mean plasma AUC ∞ of abiraterone was decreased by 55%.
recorded 2026-08-30 · last checked 2026-09-04
Q14
Was Abiraterone Acetate studied with fasting?
fasting is named in Abiraterone Acetate's label sentences: "This study was conducted to assess the bioequivalence between generic and branded 250 mg abiraterone acetate tablets in healthy Chinese participants under fasting conditions." openfda-label+europepmc · 2026-08-30
1 recorded statement; fasting
Show the evidence
fasting
This study was conducted to assess the bioequivalence between generic and branded 250 mg abiraterone acetate tablets in healthy Chinese participants under fasting conditions.
recorded 2026-08-30 · last checked 2026-09-04
Q15
What is recorded about Abiraterone Acetate and autophagy?
"Functional studies revealed that miR-143 inhibition promoted cell survival and autophagy, while its overexpression restored abiraterone acetate sensitivity." — where Abiraterone Acetate and autophagy appear together. Europe PMC · pathway abstract search · 2026-08-10
"Functional studies revealed that miR-143 inhibition promoted cell survival and autophagy, while its overexpression restored abiraterone acetate sensitivity."
PMID 41446858
"These findings demonstrate that miR-143 downregulation contributes to abiraterone acetate resistance in prostate cancer by activating the JNK/p-Bcl2-Beclin1 signaling axis and promoting autophagy."
PMID 42646605
"Because advanced prostate cancer frequently exploits enhanced autophagy as a defense mechanism against therapy-induced stress (e.g., from abiraterone), the pharmacological modulation of miRNA levels presents a tremendous opportunity to block the tumor's escape route and overcome drug resistance."
mTOR
PMID 28314838
"The combination of standard dose abiraterone acetate and BEZ235, a pan-class I PI3K and mTORC1/2 inhibitor, was poorly tolerated in men with progressive mCRPC.Although the clinical development of BEZ235 has been discontinued in prostate cancer, agents that more selectively target PI3K-AKT-mTOR signaling may have a more favorable therapeutic index and should continue to be explored."
PMID 28314838
"This phase I study evaluated the safety and tolerability of abiraterone acetate and prednisone combined with BEZ235, a dual PI3K and mTORC1/2 inhibitor, in men with progressive metastatic castration resistant prostate cancer (mCRPC) who have not received prior chemotherapy."
PMID 35363301
"To report efficacy and safety of samotolisib (LY3023414; PI3K/mTOR dual kinase and DNA-dependent protein kinase inhibitor) plus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) following cancer progression on abiraterone."
recorded 2026-08-10 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 11 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.